Lupkynis (voclosporin) is a medication that, used in combination with other immunosuppressive agents, is effective in treating adults with active lupus nephritis (LN). LN is a serious complication of systemic lupus erythematosus that can cause inflammation and damage to the kidneys. Clinical trials have shown that voclosporin induces complete remission at a higher rate than standard therapy, with a lower rate of treatment failure or worsening of the disease. Although voclosporin has a lower risk of toxicity and drug interactions, side effects like gastrointestinal symptoms and infections have been reported.